Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Zhang (Nanjing, China), K. Jones (SF, United States of America), N. Achtar-Zadeh (SF, United States of America), J. Kukreja (SF, United States of America), P. Wolters (SF, United States of America), (SF, United States of America). Histopathologic and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib. 2920

Member's Comments

No comment yet.

Related content which might interest you: Prognostic Factors in Patients with Idiopathic Pulmonary Fibrosis; Evaluation using Quantitative CT Analysis of Fibrosis and Emphysema Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Alveolar Macrophages Produced from Resected Lungs of Patients with Pulmonary Tuberculosis Source: International Congress 2017 – Microbiology and laboratory techniques to monitor NTM infections Year: 2017 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Sensitivity analyses from the INPULSIS™ trials of nintedanib Source: International Congress 2014 – Clinical trials in IPF Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 Quantitative Assessment of Thoracic Muscles in Patients with Idiopathic pulmonary fibrosis :Relationship with Prognosis Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 The Effects Of Respiratory Viruses on The Acute Pulmonary Exacerbations In Cystic Fibrosis Patients Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019